

1 **SCIENTIFIC REPORT:** Controlling the Mitochondrial Protonmotive Force with Light to Impact
2 Cellular Stress Resistance

3 **Running title:** Energizing Mitochondria with Light

4 Brandon J. Berry¹, Adam J. Trewin², Alexander S. Milliken¹, Aksana Baldzizhar², Andrea M.
5 Amitrano^{3,4}, Minsoo Kim^{3,4}, Andrew P. Wojtovich^{1,2*}

6 ¹University of Rochester Medical Center, Department of Pharmacology and Physiology, 575
7 Elmwood Ave., Rochester NY, 14642. Box 711/604. United States of America. Phone: 585-275-
8 4613.

9 ²University of Rochester Medical Center, Department of Anesthesiology and Perioperative
10 Medicine, 575 Elmwood Ave., Rochester NY, 14642 Box 711/604. United States of America.
11 Phone: 585-275-4613.

12 ³Department of Pathology, University of Rochester Medical Center, Box 609, 601 Elmwood
13 Ave., Rochester, NY 14642, USA

14 ⁴Department of Microbiology and Immunology, University of Rochester Medical Center, Box
15 609, 601 Elmwood Ave., Rochester, NY 14642, USA
16

17 brandon_berry@urmc.rochester.edu

18 a.trewin@deakin.edu.au

19 alexander_milliken@urmc.rochester.edu

20 aksana_baldzizhar@urmc.rochester.edu

21 Andrea_Amitrano@urmc.rochester.edu

22 Minsoo_Kim@urmc.rochester.edu

23 *Corresponding author

24 andrew_wojtovich@urmc.rochester.edu

25 Keywords: metabolism, anoxia, hypoxia, uncoupling, ischemia reperfusion

26 **FINAL CHARACTER COUNT:** 25,817

27

28 **ABSTRACT**

29 Mitochondrial respiration generates an electrochemical proton gradient across the mitochondrial
30 inner membrane called the protonmotive force (PMF) to drive diverse functions and make ATP.
31 Current techniques to manipulate the PMF are limited to its dissipation; there is no precise,
32 reversible method to increase the PMF. To address this issue, we used an optogenetic
33 approach and engineered a mitochondria-targeted light-activated proton pumping protein we
34 called mitochondria-ON (mtON) to selectively increase the PMF. Here, mtON increased the
35 PMF light dose-dependently, supported ATP synthesis, increased resistance to mitochondrial
36 toxins, and modulated energy-sensing behavior in *Caenorhabditis elegans*. Moreover, transient
37 mtON activation during hypoxia prevented the well-characterized adaptive response of hypoxic
38 preconditioning. Our novel optogenetic approach demonstrated that a decreased PMF is both
39 necessary and sufficient for hypoxia-stimulated stress resistance. Our results show that
40 optogenetic manipulation of the PMF is a powerful tool to modulate metabolic and cell signaling
41 outcomes.

42

43 **INTRODUCTION**

44 Mitochondria generate an electrochemical proton gradient known as the protonmotive
45 force (PMF). This consists of an electrical charge gradient, or membrane potential ($\Delta\psi_m$), and a
46 pH gradient (ΔpH) that drives energy availability and controls diverse physiologic outputs
47 (Garrido, Galluzzi et al., 2006, Rizzuto, De Stefani et al., 2012, Shadel & Horvath, 2015). The
48 PMF is generated by proton pumping respiratory complexes of the electron transport chain
49 (ETC) located in the mitochondrial inner membrane (IM). ETC dysfunction can lead to loss of
50 PMF and a diverse range of pathologies (Berry, Trewin et al., 2018, Dingley, Polyak et al.,
51 2010). For example, because the ETC consumes O_2 to establish the PMF, the PMF is

52 decreased under pathologic hypoxic conditions. The mechanistic link between acute changes in
53 the PMF and downstream physiologic changes are poorly understood (Chalmers, Saunter et al.,
54 2015, Santo-Domingo, Giacomello et al., 2013), and research is focused on developing new
55 techniques to elucidate these pathways (Chalmers, Caldwell et al., 2012, Glancy, Hartnell et al.,
56 2018).

57 Stroke is a common pathology in which cells undergo hypoxia and rapid reoxygenation
58 that causes changes in the PMF and compromises mitochondrial functions. Changes in the PMF
59 during hypoxia and reoxygenation influence cell-survival outcomes via mechanisms that are not
60 fully understood (Murphy & Hartley, 2018, Solaini, Baracca et al., 2010, Yang, Mukda et al.,
61 2018, Zhang, Trushin et al., 2016). Selectively increasing the PMF to distinguish cause and
62 effect in hypoxic models is necessary to open new avenues of investigation that may reveal
63 important metabolic changes that occur in stroke.

64 There are several techniques that allow experimental modulation of the PMF, but most
65 are pharmacologic and therefore irreversible and not cell- or tissue-specific. Herein, we take a
66 novel approach to overcome these barriers to precisely control the PMF by using optogenetics,
67 adapting an approach used recently to dissipate the PMF (Ernst, Xu et al., 2019, Tkatch, Greotti
68 et al., 2017). One family of widely-used optogenetic proteins are bacteriorhodopsin-related light-
69 activated proton pumps. These proteins pump protons across membranes in response to
70 specific wavelengths of light, and are often used to study physiology by modulating
71 electrochemical gradients at the plasma membrane (Chow, Han et al., 2010, Husson, Liewald et
72 al., 2012, Kandori, 2015). Only recently have precise optogenetic techniques been applied to
73 compartmentalized cellular events using light-activated proteins targeted to organelles (Ernst,
74 Xu et al., 2018, Rost, Schneider et al., 2015, Tkatch et al., 2017, Trewin, Bahr et al., 2019,
75 Trewin, Berry et al., 2018a). Rather than using a non-specific cation channel to permeabilize the
76 IM and dissipate the PMF, here we target the light-activated proton pump from the fungal
77 organism *Leptosphaeria maculans* (Chow et al., 2010, Waschuk, Bezerra et al., 2005) to

78 mitochondria and selectively increase the PMF. We call this optogenetic tool mitochondria-ON
79 (mtON) due to its ability to mimic the proton pumping activity of the ETC in response to light,
80 independent of oxygen or substrate availability.

81 We validated mtON using the well-characterized genetic model organism, *C. elegans*
82 (Butler, Ventura et al., 2010, Dingley et al., 2010, Tsang & Lemire, 2003). Using hypoxia and
83 reoxygenation, we tested the hypothesis that hypoxia adaptation through preconditioning
84 requires a decreased PMF. Our data demonstrate that transient loss of PMF during
85 preconditioning is necessary and sufficient for resistance to hypoxia. By probing the
86 evolutionarily conserved hypoxia adaptation response (Pena, Sherman et al., 2016, Wang, Lim
87 et al., 2019, Wojtovich, Nadtochiy et al., 2012b, Wojtovich, Nadtochiy et al., 2013), we show that
88 tools like mtON allow precise determination of cause and effect in physiologic models.

89

90 **RESULTS & DISCUSSION**

91 **Light-activated proton pump mitochondria-ON (mtON) is expressed in mitochondria.**

92 Using a ubiquitously-expressed gene promoter (*Peft-3*), we directed expression of a
93 light-activated proton pump to the mitochondrial IM in *C. elegans*. Mitochondrial localization was
94 achieved by fusion of the proton pump to an N-terminal mitochondrial targeting sequence of the
95 IMMT1 protein (Fischer, Igoudjil et al., 2011, John, Shang et al., 2005) in an orientation that
96 allows proton pumping from the mitochondrial matrix towards the intermembrane space to
97 increase the PMF in response to light (Fig. 1A). Using a C-terminal GFP fusion for subcellular
98 visualization, and MitoTrackerTM CMXRos, we observed overlap of green and red fluorescence
99 in *C. elegans* tissues, indicating the intended mitochondrial targeting (Fig. 1B & Fig. EV 1). We
100 confirmed the expression of mtON in isolated mitochondrial preparations by immunoblot against
101 GFP and observed a band at the predicted molecular weight of 82 kDa (Fig. 1C).

102


103 **mtON activation increases the PMF.**

104 Proton pumping activity of mtON requires the cofactor all trans-retinal (ATR) (Okazaki &
105 Takagi, 2013, Sumii, Furutani et al., 2005, Waschuk et al., 2005). Because *C. elegans* do not
106 produce ATR endogenously, exogenous supplementation is required for the light-activated
107 proton pump to function (Kandori, 2015, Takahashi & Takagi, 2017). Thus, we were able to
108 control for the expression of mtON (and the included GFP) in functional and non-functional
109 forms, depending on whether ATR was supplemented, in addition to the use of light controls
110 (Fig. EV 2A-D).

111 To test if mtON was capable of generating a PMF we measured the $\Delta\psi_m$ component
112 using the indicator tetramethylrhodamine ethyl ester (TMRE) in isolated *C. elegans*
113 mitochondria. TMRE is a fluorescent lipophilic cation that will accumulate in mitochondria
114 proportionally with the $\Delta\psi_m$. At the quenching concentration of TMRE used, fluorescence is low
115 at the $\Delta\psi_m$ of intact, energized isolated mitochondria. Upon loss of the $\Delta\psi_m$, TMRE redistributes
116 to the extramitochondrial space resulting in increased fluorescence due to dequenching of
117 TMRE (Fig. 2A). Under non-phosphorylating conditions in the absence of added substrate to
118 fuel ETC activity, mtON activation was able to polarize the $\Delta\psi_m$ as much as ETC-driven
119 respiration (Fig. 2B) light dose dependently (Fig. EV 3A). These data show that more photons
120 result in increased polarization of the PMF, which is in line with the biophysical studies of the
121 proton pump (Chow et al., 2010). While using the non-functional pump (no ATR), light had no
122 effect on $\Delta\psi_m$ (Fig. 2B).

123 When protons are pumped out of mitochondria during respiration the matrix pH
124 increases (Porcelli, Ghelli et al., 2005). Thus, we measured pH changes in the mitochondrial
125 matrix in response to light to test this parameter as another readout of mtON activity. Using a
126 ratiometric pH indicator, BCECF-AM, we found that matrix pH increased in response to mtON
127 activation, mimicking the effect of succinate driven respiration (Fig. 2C&D). mtON-stimulated

128 changes in matrix pH and $\Delta\psi_m$ were sensitive to the protonophore FCCP, demonstrating that
129 mtON polarizes the PMF, as measured by both the $\Delta\psi_m$ and the ΔpH .



130

131 **Figure 1 - Light-activated proton pump mitochondria-ON (mtON) is expressed in mitochondria.**


132

133 **A** Schematic depicting the targeting strategy to localize mtON to the mitochondrial inner membrane (IM).
134 The electron transport chain (ETC) complexes generate the endogenous mitochondrial PMF by proton
135 pumping, represented by the + and - across the IM. Mitochondrial ATP synthase utilizes the PMF to
136 convert ADP to ATP. The N-terminal mitochondria target sequence from the IMMT1 protein shown in red;
137 GFP shown in green. In response to light, mtON pumps protons from the mitochondrial matrix to the
138 intermembrane space (IMS).

139 **B** Confocal images demonstrate overlap of GFP tagged mtON with MitoTrackerTM Red CMXRos stained
140 *C. elegans* hypodermal mitochondria. Scale bar 10 μm .

141

142 **C** Immunoblot comparing the cytosolic supernatant and the mitochondria-enriched pellet of isolation
143 fractions. GFP-tagged mtON migrates at the predicted molecular weight of 82 kDa accounting for the
144 mitochondria-target sequence, the proton pump, and GFP. mtON is observed only in the mitochondrial
145 fraction compared to marker proteins HSP60 (mitochondria) and actin (cytosol). All blots are from the
146 same lanes on one membrane.



147

148 **Figure 2 - mtON activation increases the PMF.**

149 **A** Representative TMRE fluorescence traces in arbitrary units (a.u.) before and after $\Delta\psi_m$ dissipation with
 150 FCCP. Dashed lines indicate where FCCP was added. +/- ATR traces were performed in the absence of
 151 succinate. mtON activation was continuous throughout the traces. Light green trace is from mitochondria
 152 with ATR, gray traces are without.

153 **B** Quantification of change in fluorescence (ΔF) normalized to the maximum change in fluorescence
154 given by succinate respiration (ΔF_{\max}) for each mitochondrial preparation. Data are from the maximum
155 light dose in Fig. EV 3A. Two-way ANOVA with Sidak's test for multiple comparisons, * $p = 0.0469$, +ATR
156 succinate vs. +ATR +light $p = 0.9978$, $n = 6$ mitochondrial isolations. Bars are means \pm SEM.

157 **C** Representative BCECF-AM 490/440 nm ratio trace. Ratio of 545 nm fluorescence intensity at either
158 440 or 490 nm excitation. Dashed lines are where light or FCCP treatment occurred. Light green trace is
159 from mitochondria with ATR, gray traces are without.

160 **D** Quantification of change in BCECF-AM fluorescence ratio normalized to maximum change given by
161 succinate matrix alkalization. Two-way ANOVA with Sidak's test for multiple comparisons, -ATR succinate
162 vs. -ATR, +light * $p = 0.0212$, +ATR succinate vs. +ATR light $p = 0.999$, +ATR succinate vs. +ATR,-light p
163 = 0.0237, +ATR, +light vs, +ATR, -light $p = 0.0474$, $n = 3$ mitochondrial isolations.

164 **E** ATP levels normalized to total ATP synthesis given by succinate respiration. Data from Fig. EV 3B.
165 Succinate data shown for comparison after normalization. Two-way ANOVA with Sidak's test for multiple
166 comparisons, * $p = 0.0011$, +ATR succinate vs +ATR light $p = 0.5680$, $n = 3 - 7$ assays across two
167 mitochondrial isolations.

168 **F** O_2 required to consume 50 nmoles of ADP after mtON activation. Data are the maximum illumination
169 from Fig. EV 4D using time-matched dark conditions, One-way ANOVA * $p = 0.013$ (-ATR, -light vs. +ATR,
170 +light $p = 0.010$. -ATR, +light vs. +ATR, +light $p = 0.013$.) -ATR, -light $n = 4$, rest $n = 5$ mitochondrial
171 preparations.

172

173 **mtON increases ATP synthesis without respiration.**


174 To further test if mtON could increase energetics, we measured ATP levels from isolated
175 mitochondria that were supplied with ADP to phosphorylate, since ATP levels are highly
176 regulated *in vivo* (Balaban, Kantor et al., 1986, Glancy, Hartnell et al., 2015, Viola & Hool, 2017,
177 Wang, Zhang et al., 2017). As expected, mtON activation increased ATP levels (Fig. 2E) light-
178 dose dependently (Fig. EV 3B), similar to the $\Delta\psi_m$ results. In mitochondria, the amount of ADP
179 converted to ATP is reliant on O_2 consumption by the ETC (Brand & Nicholls, 2011). We tested
180 if we could drive ADP conversion to ATP by generating a PMF with mtON, bypassing the
181 requirement for O_2 consumption. Respiration was consistent across all control conditions (Fig.
182 EV 4A&B), indicating no baseline differences in mitochondrial quality. Activation of mtON
183 decreased the amount of O_2 required to phosphorylate a given amount of ADP (Fig. 2F & Fig.
184 EV 4C) light dose dependently (Fig. EV 4D), indicating mtON-driven ATP production does not
185 rely on O_2 consumption. Until now, interventions to increase the PMF have involved fueling the
186 ETC, where here we show mtON generates a PMF independent of O_2 consumption or metabolic

187 substrates to provide electrons. mtON's ability to augment the PMF via optic control opens a
188 new avenue for discovery in metabolic research where complex interactions between
189 physiology and bioenergetics often obscure molecular mechanisms.

190

191 **mtON increases survival during acute ETC dysfunction.**

192 Given that mtON activity decreased reliance on the ETC *in vitro*, we tested if mtON could
193 compensate for acute ETC dysfunction *in vivo*. We exposed *C. elegans* to toxic inhibitors of
194 specific sites within ETC complexes and scored their survival in response to mtON activation.
195 Light alone had no effect on survival after inhibitor exposure in all cases (Fig. 3A-C). For
196 transgenic animals, when exposed to the complex I inhibitor rotenone, mtON was able to
197 improve survival (Fig. 3A). Rotenone toxicity is mediated chiefly through oxidative damage
198 (Ishiguro, Yasuda et al., 2001, Schmeisser, Priebe et al., 2013), and ATR alone exhibited a
199 protective effect under these conditions, possibly due to its antioxidant properties (Lee,
200 Casadesus et al., 2009, Palace, Khaper et al., 1999, Siddikuzzaman & Grace, 2013). This effect
201 was also present in wild type control experiments (Fig. EV 5A). However, the effect of mtON
202 was significantly greater than the ATR effect (Fig. EV 5A, one-way ANOVA, $p = 0.0002$), with no
203 effect in wild type animals (Fig. EV 5A&B). Activation of mtON also protected animals exposed
204 to antimycin A, a complex III inhibitor (Ishiguro et al., 2001) (Fig. 3B), and azide, a complex IV
205 inhibitor (Fig. 3C). Unlike with rotenone treatment, ATR alone did not mitigate antimycin A or
206 azide toxicity. Overall, these data indicate that mtON can partially overcome inhibited ETC
207 activity in whole organisms.



208

209 **Figure 3 - mtON improves survival during acute ETC dysfunction.**

210 **A** Day 1 adult animals were exposed to 50 μ M rotenone (ETC complex I inhibitor) for 5 hours and survival
211 was scored. Illumination was continuous throughout toxin exposure (see methods). ATR alone was
212 protective (-ATR, -light vs. +ATR, -light $p = 0.016$.) The effect of mtON activation was greater than the
213 ATR alone effect * $p = 0.01$. (-ATR, -light vs +ATR, +light $p = 0.0002$. -ATR, +light vs. +ATR, +light $p =$
214 0.0009 . $n = 3$ plates each condition).

215 **B** Animals were exposed to 50 μ M antimycin A (complex III inhibitor) and survival was scored 18 hours
216 later. * $p = 0.02$ (-ATR, -light vs +ATR, +light $p = 0.03$, -ATR, +light vs. +ATR, +light $p = 0.01$. $n = 5$ plates
217 each condition).

218 **C** Animals were exposed to 0.25 M azide (complex IV inhibitor) for 1 hour and scored for survival 1 hour
219 after recovering. * $p = 0.0002$. (-ATR, -light vs +ATR, +light $p < 0.0001$, -ATR, +light vs. +ATR, +light $p =$
220 < 0.0001 . $n = 3$ plates each condition). Statistics are one-way ANOVA with Tukey's post hoc test. Bars are
221 means \pm SEM.


222

223 **mtON affects whole-animal energy sensing.**

224 We next asked whether mtON could affect metabolic signaling. One way organisms
225 sense energy availability and preserve energy homeostasis is through the AMP-activated
226 protein kinase (AMPK) (Hardie, Ross et al., 2012). In *C. elegans* the *aak-2* gene encodes the
227 catalytic subunit ortholog of mammalian AMPK α 2. Mutation of *aak-2* has well-characterized
228 phenotypic outputs linked to energy availability, and serves as a regulator of whole-organism
229 energy sensing (Apfeld, O'Connor et al., 2004, Cunningham, Bouagnon et al., 2014). We
230 hypothesized that mtON activity would signal energy availability and decrease phosphorylation
231 of AMPK, its activated state. As such, we exposed animals expressing mtON to light in the
232 absence of food, where AMPK should be phosphorylated, and immunoblotted against
233 phosphorylated AMPK. We found that removal from food increases AMPK phosphorylation as
234 expected, and mtON activation prevented this phosphorylation (Fig. 4A). In *C. elegans*, the

235 AMPK homologue AAK-2 regulates a behavioral response to food availability (Lee, Cho et al.,
236 2008), where in the absence of food animals will increase locomotion to search for food. Based
237 on our phosphorylation results, we hypothesized that mtON activation would attenuate the
238 energy deficit signal for animals off food, suppressing their movement, and thus mimicking the
239 *aak-2* loss-of-function phenotype. We first confirmed that *aak-2* loss-of-function mutant animals
240 had decreased locomotion in the absence of food compared to wild type (Fig. 4B). In response
241 to acute mtON activation in wild type background, we observed decreased locomotion in the
242 absence of food (Fig. 4C). This effect was reversed using the AMPK activator 5-aminoimidazole-
243 4-carboxamide ribonucleotide (AICAR), indicating the mtON suppression of locomotion was
244 rescued by AMPK activity (Fig. 4C). These data suggest that mtON activity can modify
245 downstream metabolic signaling. As changing the PMF affects many aspects of metabolism that
246 are able to activate AMPK, the exact mechanism of AMPK activation in our experiments is
247 unclear. For example, AMPK is activated by increased energy demand, but also redox signaling
248 (Garcia & Shaw, 2017), and calcium signaling (Hardie, 2011). Upon further characterization in
249 these contexts mtON could be used to modulate the many cellular processes that AMPK
250 regulates (Hinchy, Gruszczuk et al., 2018, Jeon, 2016, Mihaylova & Shaw, 2011, Trewin, Berry
251 et al., 2018b).

252



253

254 **Figure 4 - mtON affects whole-animal energy sensing.**

255

256 **A** Top: Immunoblot assessing the effect of mtON activation on AMPK phosphorylation status. Top bands
 257 (~62 kDa) are phosphorylated AMPK signal, and bottom bands (~43 kDa) are actin signal. Image is from
 258 the same membrane cut to separately probe for phosphorylated AMPK (pAMPK) and actin. Bottom:
 259 Densitometry analysis showing decreased pAMPK to actin ratio, as there is no known antibody directed
 260 against total AMPK in *C. elegans*. Phosphorylation increases in the absence of food, but low
 261 phosphorylation is preserved when mtON is activated, two-way ANOVA with Sidak's test for multiple
 262 comparisons, * $p = 0.0203$, $n = 3-4$ biological replicates.

263

264 **B** Locomotion was assessed by counting body bends per minute. Wild type animals were compared to
 265 *aak-2(ok524)* mutant animals. 2-sample, 2-tailed unpaired t-test * $p < 0.0001$, wild type $n = 35$, *aak-2* $n =$
 266 39 animals across at least 3 days. Bars are means \pm standard deviation.

267

268 **C** Locomotion in response to mtON activation. Illumination was continuous throughout body bends
 269 measurement (see methods). For AAK-2 activation, animals were exposed to 1 mM AICAR for 4 hours
 270 before body bends measurement. One-way ANOVA with Tukey's post hoc test, -ATR, +light vs +ATR,
 271 +light * $p < 0.0001$, +ATR,+light vs AICAR * $p < 0.0001$. $n =$ (in order, left to right) 36, 39, 37, 46, 36
 272 animals across at least 3 days. Bars are means \pm standard deviation.


273

274 mtON inhibits hypoxia-adaptation.

275

276 We next tested if mtON could impact stress resistance. Hypoxia and reoxygenation (HR)
 277 is a pathologic insult that involves changes in the PMF that can contribute to injury and survival
 278 (Chouchani, Pell et al., 2014, Michiels, 2004, Murphy & Hartley, 2018, Sanderson, Reynolds et
 279 al., 2013, Solaini et al., 2010, Xu, Wang et al., 2001, Yang et al., 2018) depending on the
 280 context and degree of (de)polarization. In addition, the phenomenon of preconditioning (PC) is
 effectively modeled with hypoxia in *C. elegans* (Dasgupta, Patel et al., 2007, Hayakawa, Kato et

281 al., 2011, Jia & Crowder, 2008, Pena et al., 2016, Wojtovich, DiStefano et al., 2012a), where a
282 short period of hypoxia protects against a later pathologic exposure (Fig. 5B). A decreased PMF
283 before HR also mediates a protective effect (Brennan, Berry et al., 2006, Brennan, Southworth
284 et al., 2006, Ozcan, Palmeri et al., 2013), but mechanisms are debated (Shabalina &
285 Nedergaard, 2011), as understanding is complicated by lack of temporal control when using
286 pharmacologic approaches. In support of this, the protonophore FCCP, which can dissipate the
287 PMF, protected wild type animals against HR (Fig. 5C), suggesting hypoxia resistance may be
288 mediated by a decreased PMF. We combined these lines of evidence and hypothesized that
289 increasing the PMF during PC would reverse the protection against hypoxia afforded by PC. To
290 test this hypothesis we activated mtON selectively during PC (Fig. 5A). To quantify protection,
291 we subtracted the percent survival after pathologic hypoxia from the percent survival after an
292 intervention, giving the percent alive above baseline (Fig. 5C). Further highlighting the
293 importance of our control conditions, we found that light on its own was as protective as PC in
294 mtON expressing animals, and the combination of light and PC was additive (Fig. 5D).
295 However, activation of mtON during PC decreased the protection (Fig. 5D), supporting our
296 hypothesis that some of the protective effect of PC is mediated by decreasing the PMF. In
297 effect, mtON counteracts a PC-induced decrease in the PMF by restoring it to normal levels.
298 These data suggest that loss of PMF during PC is necessary for hypoxic adaptation. The FCCP
299 data corroborate our mtON findings, and demonstrate the sufficiency of PMF loss to protect
300 against hypoxia. Using mtON only during PC to boost the PMF provided temporal control that
301 had not been tested before, allowing us to determine when PMF changes have physiologic
302 effects in HR.



303

304 **Figure 5 - mtON inhibits hypoxia-adaptation.**

305

306 **A** Schematic of HR experiments. Top shows control hypoxia and reoxygenation. Below is the hypoxic
307 preconditioning (PC) protocol, survival for these two timelines shown in panel B. Third from the top shows
308 FCCP treatment protocol, calculated protection shown in panel C. Bottom two show light treatment
309 protocol + and - PC, calculated protection data from these shown in panel D.

310

311 **B** Survival after HR in day 1 adult animals is shown with hypoxic preconditioning (PC, represented by
312 diagonal stripes) 2-sample 2-tailed unpaired t-test, ctrl vs. PC * $p = 0.0035$, $n = 4$, each averaged from 3
313 technical replicates. Bars are means \pm SEM.

314

315 **C** Protection (%) is percent survival minus percent survival of control condition. PC data calculated from
316 panel B. FCCP final concentrations 0.001, 0.01, 0.1, 1 nM. One-way ANOVA with Tukey's post hoc test,
317 PC vs. 0.001 nM FCCP, $p = 0.0012$, 0.001 nM FCCP vs 0.01 FCCP, $p = 0.0142$, $n = 3 - 4$ independent
318 experiments, each averaged from 3 technical replicates. Bars are means \pm SEM.

319

320 **D** Illumination was continuous throughout PC alone, control illumination was for the same duration under
321 normoxic conditions (see methods & panel A). Two-way ANOVA comparing +ATR vs -ATR in each group.
322 * $p = 0.016$, $n =$ (in order, left to right) 11,11,4,4,6,6 independent experiments, each averaged from 3
323 technical replicates. Bars are means \pm SEM.

324

325 Our findings that protection afforded by PC relies on the transient loss of PMF suggest
326 that a decreased PMF is sufficient to elicit stress resistance at a later period. This implies that
327 interventions at the level of the PMF alone can impact cellular responses to stress. Combining
328 the mtON approach with tissue-specific gene promoters, precise spatiotemporal control could
329 be achieved in discerning the effects of mitochondrial function across tissues in whole
330 organisms. Taken together, mtON appears to be a useful tool to enable discrimination of cause
331 and effect in complex (patho)physiologic contexts that involve modest changes in mitochondrial
332 function and metabolism. Defining when changes in the PMF are adaptive and when they are
333 detrimental may advance our understanding of many pathologies and inform novel therapeutic
334 strategies that target mitochondrial function. Our findings from this approach suggest the PMF is
335 a keystone of metabolism that senses cellular stress and elicits appropriate adaptive responses
336 to maintain homeostasis.

337

338 **MATERIALS & METHODS**

339 ***Molecular biology***

340 The light-activated proton pump from *Leptosphaeria maculans* (Mac) fused to eGFP was
341 amplified from plasmid DNA pFCK-Mac-GFP, a gift from Edward Boyden (Addgene plasmid
342 #22223 (Chow et al., 2010)) (forward amplification primer:
343 ACACCTGCAGGCTTGATCGTGGACCAGTTCGA, reverse amplification primer:
344 CACAGCGGCCGCTTACTTGTACAGCTCGTCCA). The N-terminal 187 amino acids of the
345 *Immt1* gene was amplified by PCR from mouse cDNA (forward amplification primer:
346 ACAACCGGTAAAAATGCTGCGGGCCTGTCAGTT, reverse amplification primer:
347 CACCCTGCAGGTTCCCTCTGTGGTTTCAGACG). The ubiquitously expressed gene promoter
348 *Peft-3* (also known as *Peef-1A.1*) was amplified by PCR from pDD162 (forward amplification

349 primer: AACAAAGCTTGCACCTTTGGTCTTTTA, reverse amplification primer:
350 ACATCTAGAGAGCAAAGTGTTTCCCA). The body wall muscle promoter *Pmyo-3* was PCR
351 amplified from pDJ16 (forward amplification primer: ACAGCTAGCTGTGTGTGATTGCT,
352 reverse amplification primer: ACAACCGGTGCGGCAATTCTAGATGG). PCR fragments were
353 ligated into pFH6.II (pPD95.81 with a modified multi-cloning site) for *C. elegans* expression
354 using restriction digest cloning. Resulting plasmids were pJB20 (*Peft-3::IMMT1*(N-terminal 187
355 amino acids)::Mac::GFP), pJB16 (*Pmyo-3::IMMT1*(N-terminal 187 amino acids)::Mac::GFP),
356 Sanger sequencing was used to confirm plasmid sequences (Eurofins Genomics). Animals
357 were transformed by plasmid DNA microinjection with *pha-1(+)* selection in a *pha-1(e2123ts)*
358 temperature-sensitive mutant strain, where transgenic animals were selected for growth at 20°
359 C.

360

361 ***C. elegans strains growth and maintenance***

362 All animals were maintained at 20° C on nematode growth medium (NGM) seeded with OP50 *E.*
363 *Coli*. Young adult hermaphrodite animals were used for all experiments. Transgenic strains
364 were generated by plasmid DNA microinjection as described (Mello, Kramer et al., 1991). For a
365 complete strain list see Table 1. Where indicated, OP50 was supplemented with all trans-
366 Retinal to a final concentration of 100 µM on seeded NGM plates. Animals were cultured on
367 ATR-containing plates for at least one generation.

368

369 ***Fluorescence microscopy***

370 Images were taken on a FV1000 Olympus laser scanning confocal microscope using a 60x oil
371 objective (Olympus, N.A. 1.42). Diode laser illumination was at 561 nm for red fluorescence and
372 488 nm for green fluorescence. Where indicated, animals were stained with 10 µM
373 MitoTracker™ Red CMXRos for 4 hours. MitoTracker™ stain was dissolved in DMSO, diluted in

374 M9 media (22 mM KH_2PO_4 , 42 mM Na_2HPO_4 , 86 mM NaCl, 1 mM MgSO_4 , pH 7) and added to
375 OP50 seeded NGM plates (DMSO < 0.02% final) and allowed to dry. Line scan pixel intensity
376 was performed using ImageJ software.

377

378 ***Mitochondria isolation***

379 *C. elegans* mitochondria were isolated from day 1 adults as previously described (Wojtovich et
380 al., 2012a) using differential centrifugation in mannitol and sucrose-based media. Animals from
381 three 15 cm culture plates were transferred into 50 mL of M9 media in a conical tube and
382 allowed to settle by gravity on ice. Pelleted animals were rinsed with ice-cold M9 twice, and
383 once with ice-cold mitochondrial isolation media (220 mM mannitol, 70 mM sucrose,
384 5 mM MOPS, 2 mM EGTA, pH 7.4) with 0.04% BSA. After settling by gravity, supernatant was
385 removed and worms were transferred to an ice-cold mortar containing ~2 g of pure sea sand
386 per 1 mL of animals. Animals were ground with an ice-cold pestle for 1 minute and extracted
387 from the sand using mitochondrial isolation media and transferred to a 10 mL conical tube. The
388 suspension was then transferred to an ice-cold glass Dounce homogenizer and homogenized
389 with 40 strokes. The homogenate was centrifuged at 600 g for 5 minutes. Supernatant was
390 transferred to a new tube and centrifuged at 700 g for 10 minutes. The pellet was resuspended
391 in 1 mL of mitochondrial isolation media without BSA, which was centrifuged at 7000 g for 5
392 minutes. The pellet was finally resuspended in 50 μL of mitochondrial isolation media without
393 BSA. Protein concentration was quantified using the Folin-phenol method.

394

395 ***Light sources***

396 Illumination sources included a 580 nm Quantum SpectraLife LED Hybrid lamp by Quantum
397 Devices, Barneveld WI, USA (abbreviated Quantum LED), a 540-600 nm GYX module, X-Cite
398 LED1 by Excelitas, Waltham MA, USA (abbreviated XCite LED), and a 540-580 nm excitation
399 filter MVX10 Fluorescence MacroZoom dissecting microscope by Olympus (abbreviated MVX).

400 Light intensities are indicated for each experimental condition and were determined with a
401 calibrated thermopile detector (818P-010-12, Newport Corporation, Irvine, CA) and optical
402 power meter (1916-R, Newport Corporation).

403

404 ***Immunoblotting***

405 Synchronized young adult animals were exposed to 1 Hz light (Quantum LED, 0.02 mW/mm²)
406 for 4 hours, and immediately harvested with ice-cold M9 media and centrifuged at 1,000 x g for
407 1 minute. Animals were ground by plastic pestle disruption in lysis buffer (20mM Tris-HC, 100
408 mM NaCl, 1mM EDTA, 1mM DTT, 10% glycerol, 0.1% SDS, pH 7.6, 1X Halt™ protease inhibitor
409 cocktail, Thermo78429) and diluted 1:1 in sample loading buffer (100 mM Tris HCl, 10% v/v
410 glycerol, 10% SDS, 0.2% w/v bromophenol blue, 2% v/v β-mercaptoethanol). These samples
411 were heated at 95 °C for 5 minutes. Isolated mitochondrial samples were prepared as described
412 above and diluted 1:1 in sample loading buffer with 1% SDS. 30 µg samples were loaded to
413 7.5% polyacrylamide gels and separated by SDS-PAGE. Proteins were transferred to
414 nitrocellulose membranes and blocked in 5% nonfat milk/TBST (50 mM Tris, 150 mM NaCl,
415 0.05% Tween 20, pH 8.0) for 1 h at room temperature. Membranes were incubated at 4°C in
416 primary antibodies diluted 1:1000 in 5% bovine serum albumin: anti-GFP (ClonTech Living
417 Colours #ab632375), anti-HSP60 (Department of Biology, Iowa City, IA 52242. Developmental
418 Studies Hybridoma Bank, University of Iowa Department of Biology, Iowa City, IA 52242), (Cell
419 Signaling, #4188), anti-Actin (Abcam #ab14128), and 1:10,000 anti-phospho-AMPKα).
420 Membranes were washed in TBST and incubated in horseradish peroxidase-conjugated
421 secondary antibodies: anti-rabbit IgG (Cell Signaling #7074S) or anti-mouse IgG (Thermo
422 Scientific #32430, lot #RF234708) for 1 hour at room temperature. Proteins were visualized
423 using ECL (Clarity Western ECL Substrate, Bio Rad) by chemiluminescence (ChemiDoc, Bio
424 Rad). Densitometry was performed using Image Lab software (version 5.2.1).

425

426 ***Mitochondrial membrane potential measurement***

427 Isolated mitochondria at 0.5 mg/mL were stirred in mitochondrial respiration buffer (MRB: 120
428 mM KCl, 25 mM sucrose, 5 mM MgCl₂, 5 mM KH₂PO₄, 1 mM EGTA, 10 mM HEPES, 1 mg/mL
429 FF-BSA, pH 7.35) at 25° C in the presence of 2 μM rotenone, and 5 mM succinate where
430 indicated. 300 nM tetramethylrhodamine, ethyl ester (TMRE, ThermoFisher, T669) was added
431 to observe mitochondrial membrane potential in quench mode. Under quenching conditions
432 TMRE fluorescence is low in the presence of a $\Delta\psi_m$. Upon addition of a protonophore (e.g.
433 FCCP), TMRE will exit mitochondria and dequench and increase total fluorescence (Chouchani
434 et al., 2014, Perry, Norman et al., 2011). TMRE signal was measured by Cary Eclipse
435 Fluorescence Spectrophotometer (Agilent Technologies) using a 335-620 nm excitation filter
436 and a 550-1100 nm emission. Illumination was performed continuously throughout all
437 measurements (555 nm, 0.0016 mW/mm²). Increasing illumination time exposed mitochondria
438 to more photons (calculated as fluence, J/cm²). After stable baseline measurements with or
439 without succinate, 2 μM FCCP was added to completely depolarize mitochondria. The average
440 fluorescence intensity after addition of 2 μM FCCP (maximum fluorescence in quench mode)
441 was subtracted from the starting test condition to give a change in fluorescence corresponding
442 to changes in $\Delta\psi_m$ (ΔF for conditions without succinate, and ΔF_{max} for conditions with succinate).
443 To represent polarization of the $\Delta\psi_m$, we used the ratio of change in fluorescence (ΔF , FCCP
444 fluorescence minus experimental fluorescence) to the maximum change in fluorescence
445 generated by succinate-driven $\Delta\psi_m$ (ΔF_{max}).

446

447 ***Mitochondrial matrix pH measurement***

448 The ratiometric pH indicator BCECF-AM (ThermoFisher, B1170) was used to measure pH
449 changes in the mitochondrial matrix (Aldakkak, Stowe et al., 2010) in response to succinate

450 respiration or mtON activation. Isolated mitochondria (~200 μ L per isolation) were incubated at
451 room temperature with 50 μ M BCECF-AM for 10 minutes with periodic mixing. Mitochondria
452 were then pelleted at 7000 g for 5 minutes at 4° C, isolation media replaced and pelleted again
453 to remove extramitochondrial BCECF-AM. Isolated mitochondrial suspensions were then
454 assayed under the same conditions as in the mitochondrial membrane potential measurements
455 described above. Ratiometric fluorescent signal was measured by Cary Eclipse Fluorescence
456 Spectrophotometer (Agilent Technologies) using 440 and 490 nm excitation wavelengths and
457 545 nm emission. The fluorescence intensity ratio at 545 nm of 490/440 nm excitation
458 wavelengths was used to represent pH changes in the mitochondrial matrix. Light treatment was
459 0.16 J/cm² (XCite LED, 0.02 mW/mm²), and 2 μ M FCCP was used at the end of each trace to
460 establish baseline signal.

461

462 ***ATP measurement***

463 Relative ATP levels were determined in isolated mitochondria using a luciferase
464 bioluminescence kit according to manufacturer's instructions (Invitrogen™ Molecular Probes™,
465 A22066). Mitochondria were stirred in MRB at 0.5 mg/mL with 1 mg/mL fat free BSA, 600 μ M
466 ADP, 2 μ M rotenone. 5 mM succinate for a control for maximum ATP level, and 0.001 mg/mL
467 oligomycin A was used as a zero ATP synthesis control. Mitochondrial suspensions were
468 immediately frozen with liquid nitrogen after 1, 5, or 10 minutes light exposure (XCite LED, 0.02
469 mW/mm²). Samples were then thawed on ice, centrifuged at 14,800 g, and supernatant was
470 collected and run at 1:100 dilution in MRB in the luminescence assay. Oligomycin A control
471 values were subtracted from experimental reads, and data were then normalized to luminescent
472 signal from succinate control samples (complete ADP conversion confirmed by monitoring O₂
473 consumption rate transitions).

474

475 ***Mitochondrial O₂ consumption***

476 O₂ consumption was measured using a Clark-type O₂ electrode (S1 electrode disc, DW2/2
477 electrode chamber and Oxy-Lab control unit, Hansatech Instruments, Norfolk UK) at 25° C.
478 Isolated mitochondria were stirred in MRB at 1 mg/mL with 1 mg/mL fat free BSA. Substrates
479 and inhibitors were added by syringe port (100 μM ADP, 2 μM rotenone, 5 mM succinate).
480 Given excess succinate as substrate for ETC respiration, we measured the amount of O₂
481 required to convert 50 nmol of ADP to ATP and established a baseline for comparison. To test
482 mtON activity, we illuminated mitochondria as in the ATP measurement, for 1, 5, or 10 minutes
483 in the presence of ADP without succinate to allow for mtON conversion of ADP to ATP. Any
484 remaining ADP was then converted using O₂-dependent ETC respiration upon succinate
485 addition (Fig. EV4C). Slopes were calculated from plots of O₂ concentration versus time to give
486 rates of O₂ consumption during ADP respiration, ADP+succinate respiration, and respiration
487 after ADP had been entirely consumed. The intersections of these three rates were used to
488 calculate total amount of O₂ consumed during ADP+succinate respiration. Light activation of
489 mitochondria (XCite LED, 0.02 mW/mm²) during ADP respiration alone was carried out for
490 differing lengths of time to test the ability of mtON to drive ADP consumption before succinate
491 was added. Dark control was 10 minutes of no illumination before addition of succinate.

492

493 ***ETC inhibitor assays***

494 Experiments were performed on at least three separate days, using 15-100 young adult animals
495 per plate. Seeded plates were supplemented with rotenone (50 μM final concentration), or
496 antimycin A (50 μM final concentration) 24 hours before animals were transferred onto them.
497 For azide toxicity animals were placed in M9 buffer with 250 mM azide. Control plates were kept
498 in the dark and experimental plates were exposed to 1 Hz light (Quantum LED, 0.02 mW/mm²)
499 for the duration of the experiment. For rotenone, surviving animals were scored after 5 hours.
500 For antimycin A, animals were scored 16 hours after exposure. For azide, animals were
501 exposed for one hour in M9 and allowed to recover for 1 hour on a seeded culture plate, then

502 survival was scored. Azide experimental plates were exposed to light (XCite LED, 0.19
503 mW/mm²) for the duration of azide treatment and recovery. For all toxins, animals that were
504 moving or those that moved in response to a light touch to the head were scored as alive.

505

506 ***Locomotion assay***

507 Locomotion was scored by counting the number of body bends in 15 seconds immediately after
508 being transferred off OP50 food (Sawin, Ranganathan et al., 2000) (n = 36-46 animals scored
509 on at least 2 separate days). 1 body bend was scored as a deflection of direction of motion of
510 the posterior pharyngeal bulb (Tsalik & Hobert, 2003). For AMPK activation, animals were
511 placed on plates containing 1 mM AICAR 4 hours before counting body bends. AICAR was
512 dissolved in M9 buffer, added directly onto OP50 seeded plates and allowed to dry. Illumination
513 was continuous through measurements (MVX, 0.265 mW/mm²).

514

515 ***Hypoxia and reoxygenation***

516 Experiments were carried out using a hypoxic chamber (Coy Lab Products, 5%/95% H₂/N₂ gas,
517 palladium catalyst) at 26° C with 50-100 animals per plate. O₂ was less than 0.01%. Hypoxic
518 preconditioning (PC) duration was 4 hours, and control animals were incubated at 26° C in room
519 air for the same time. 1 Hz illumination (Quantum LED, 0.02 mW/mm²) was carried out during
520 PC period alone. Hypoxic exposure was for 18.5 hours, 21 hours after PC. 24 hours after
521 hypoxia exposure, animals that were moving or those that moved in response to a light touch to
522 the head were scored as alive. Data from days where PC was at least 15% effective for both
523 +ATR and -ATR were used. Animals supplemented with ATR were allowed to lay eggs onto
524 plates with no ATR that were subsequently used for HR experiments to minimize confounding
525 effects of ATR. ATR from the parent animal was sufficient to provide active mtON in progeny as
526 tested by the azide toxin assay described above. Only progeny from parents supplemented with
527 ATR were significantly protected against azide upon illumination (tested by One-way ANOVA, -

528 ATR, -light [17.3% survival] vs. +ATR, +light [66.8% survival] $p = 0.0054$, -ATR, +light [32.5%
529 survival] vs. +ATR, +light $p = 0.0395$, +ATR, -light [27.5% survival] vs. +ATR, +light $p = 0.0199$,
530 $DF = 11$, $F = 8.94$). PC experiments were represented as protection (%), where baseline
531 survival was subtracted to correct for protection from ATR (-ATR survival: $34.4 \pm 14.4\%$, +ATR
532 survival: $49.7 \pm 20.3\%$, 2 sample 2-tailed paired t-test, $p = 0.033$, $n = 12$ independent
533 experiments). FCCP dissolved in ethanol was deposited onto seeded NGM plates to the final
534 concentrations indicated in the figure legend (Fig. 5C).

535

536 **Statistics**

537 One-way ANOVA was used when comparing only our four experimental conditions (Fig. EV2).
538 Two-way ANOVA was used when comparing our conditions with other variables, such as +/-
539 succinate. Shapiro-Wilkes normality tests were used to determine whether parametric or non-
540 parametric tests should be used. See figure legends for detailed statistical information and post-
541 hoc tests.

542

543 **DATA AVAILABILITY**

544 All data are presented in the manuscript, and raw files will be made available upon request.

545

546 **ACKNOWLEDGEMENTS**

547 Work in the laboratory of A.P.W. is supported by a grant from National Institutes of Health (R01
548 NS092558) and institutional funds from the University of Rochester; B.J.B. is supported by an
549 American Heart Association Predoctoral Fellowship (18PRE33990054) and an Institutional Ruth
550 L. Kirschstein National Research Service Award (NIH T32 GM068411). A.J.T current address:
551 Institute for Physical Activity and Nutrition (IPAN), Deakin University, Burwood, Australia. We
552 thank the members of the mitochondrial research groups at University of Rochester Medical

553 Center for helpful discussions, suggestions, and guidance. Some strains were provided by the
554 CGC, which is funded by NIH Office of Research Infrastructure Programs (P40 OD010440).

555

556 **AUTHOR CONTRIBUTIONS**

557 B.J.B. and A.P.W. designed the research. B.J.B., A.J.T., A.S.M., A.B. and A.M.A. performed
558 experiments. M.K. provided critical review of the results and manuscript. B.J.B. analyzed the
559 data and wrote the manuscript. All authors approved the final version of the manuscript.

560

561 **CONFLICT OF INTEREST**

562 The authors declare that they have no conflict of interest.

563

564 **References**

565

- 566 Aldakkak M, Stowe DF, Cheng Q, Kwok WM, Camara AK (2010) Mitochondrial matrix K⁺ flux
567 independent of large-conductance Ca²⁺-activated K⁺ channel opening. *Am J Physiol Cell Physiol* 298:
568 C530-41
- 569 Apfeld J, O'Connor G, McDonagh T, DiStefano PS, Curtis R (2004) The AMP-activated protein kinase AAK-
570 2 links energy levels and insulin-like signals to lifespan in *C. elegans*. *Genes Dev* 18: 3004-9
- 571 Balaban RS, Kantor HL, Katz LA, Briggs RW (1986) Relation between work and phosphate metabolite in
572 the in vivo paced mammalian heart. *Science* 232: 1121-3
- 573 Berry BJ, Trewin AJ, Amitrano AM, Kim M, Wojtovich AP (2018) Use the Protonmotive Force:
574 Mitochondrial Uncoupling and Reactive Oxygen Species. *J Mol Biol*
- 575 Brand MD, Nicholls DG (2011) Assessing mitochondrial dysfunction in cells. *Biochem J* 435: 297-312
- 576 Brennan JP, Berry RG, Baghai M, Duchen MR, Shattock MJ (2006) FCCP is cardioprotective at
577 concentrations that cause mitochondrial oxidation without detectable depolarisation. *Cardiovasc Res*
578 72: 322-30
- 579 Brennan JP, Southworth R, Medina RA, Davidson SM, Duchen MR, Shattock MJ (2006) Mitochondrial
580 uncoupling, with low concentration FCCP, induces ROS-dependent cardioprotection independent of
581 KATP channel activation. *Cardiovasc Res* 72: 313-21
- 582 Butler JA, Ventura N, Johnson TE, Rea SL (2010) Long-lived mitochondrial (Mit) mutants of
583 *Caenorhabditis elegans* utilize a novel metabolism. *FASEB J* 24: 4977-88


584 Chalmers S, Caldwell ST, Quin C, Prime TA, James AM, Cairns AG, Murphy MP, McCarron JG, Hartley RC
585 (2012) Selective uncoupling of individual mitochondria within a cell using a mitochondria-targeted
586 photoactivated protonophore. *J Am Chem Soc* 134: 758-61
587 Chalmers S, Saunter CD, Girkin JM, McCarron JG (2015) Flicker-assisted localization microscopy reveals
588 altered mitochondrial architecture in hypertension. *Sci Rep* 5: 16875
589 Chouchani ET, Pell VR, Gaude E, Aksentijevic D, Sundier SY, Robb EL, Logan A, Nadtochiy SM, Ord ENJ,
590 Smith AC, Eyassu F, Shirley R, Hu CH, Dare AJ, James AM, Rogatti S, Hartley RC, Eaton S, Costa ASH,
591 Brookes PS et al. (2014) Ischaemic accumulation of succinate controls reperfusion injury through
592 mitochondrial ROS. *Nature* 515: 431-435
593 Chow BY, Han X, Dobry AS, Qian X, Chuong AS, Li M, Henninger MA, Belfort GM, Lin Y, Monahan PE,
594 Boyden ES (2010) High-performance genetically targetable optical neural silencing by light-driven proton
595 pumps. *Nature* 463: 98-102
596 Cunningham KA, Bouagnon AD, Barros AG, Lin L, Malard L, Romano-Silva MA, Ashrafi K (2014) Loss of a
597 neural AMP-activated kinase mimics the effects of elevated serotonin on fat, movement, and hormonal
598 secretions. *PLoS Genet* 10: e1004394
599 Dasgupta N, Patel AM, Scott BA, Crowder CM (2007) Hypoxic preconditioning requires the apoptosis
600 protein CED-4 in *C. elegans*. *Curr Biol* 17: 1954-9
601 Dingley S, Polyak E, Lightfoot R, Ostrovsky J, Rao M, Greco T, Ischiropoulos H, Falk MJ (2010)
602 Mitochondrial respiratory chain dysfunction variably increases oxidant stress in *Caenorhabditis elegans*.
603 *Mitochondrion* 10: 125-36
604 Ernst P, Xu N, Qu J, Chen H, Goldberg MS, Darley-Usmar V, Zhang JJ, O'Rourke B, Liu X, Zhou L (2019)
605 Precisely Control Mitochondria with Light to Manipulate Cell Fate Decision. *Biophys J*
606 Ernst P, Xu N, Song J, Qu J, Chen H, Goldberg MS, Zhang J, O'Rourke B, Liu X, Zhou L (2018) Precisely
607 control mitochondrial membrane potential with light to manipulate cell fate decisions. *bioRxiv*: 469668
608 Fischer LR, Igoudjil A, Magrane J, Li Y, Hansen JM, Manfredi G, Glass JD (2011) SOD1 targeted to the
609 mitochondrial intermembrane space prevents motor neuropathy in the Sod1 knockout mouse. *Brain*
610 134: 196-209
611 Garcia D, Shaw RJ (2017) AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic
612 Balance. *Mol Cell* 66: 789-800
613 Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, Kroemer G (2006) Mechanisms of cytochrome c
614 release from mitochondria. *Cell Death Differ* 13: 1423-33
615 Glancy B, Hartnell LM, Combs CA, Femnou A, Sun J, Murphy E, Subramaniam S, Balaban RS (2018) Power
616 Grid Protection of the Muscle Mitochondrial Reticulum. *Cell Rep* 23: 2832
617 Glancy B, Hartnell LM, Malide D, Yu ZX, Combs CA, Connelly PS, Subramaniam S, Balaban RS (2015)
618 Mitochondrial reticulum for cellular energy distribution in muscle. *Nature* 523: 617-20
619 Hardie DG (2011) AMP-activated protein kinase: an energy sensor that regulates all aspects of cell
620 function. *Genes Dev* 25: 1895-908
621 Hardie DG, Ross FA, Hawley SA (2012) AMPK: a nutrient and energy sensor that maintains energy
622 homeostasis. *Nat Rev Mol Cell Biol* 13: 251-62
623 Hayakawa T, Kato K, Hayakawa R, Hisamoto N, Matsumoto K, Takeda K, Ichijo H (2011) Regulation of
624 anoxic death in *Caenorhabditis elegans* by mammalian apoptosis signal-regulating kinase (ASK) family
625 proteins. *Genetics* 187: 785-92
626 Hinchy EC, Gruszczuk AV, Willows R, Navaratnam N, Hall AR, Bates G, Bright TP, Krieg T, Carling D,
627 Murphy MP (2018) Mitochondria-derived ROS activate AMP-activated protein kinase (AMPK) indirectly.
628 *J Biol Chem* 293: 17208-17217
629 Husson SJ, Liewald JF, Schultheis C, Stirman JN, Lu H, Gottschalk A (2012) Microbial light-activatable
630 proton pumps as neuronal inhibitors to functionally dissect neuronal networks in *C. elegans*. *PLoS One* 7:
631 e40937

632 Ishiguro H, Yasuda K, Ishii N, Ihara K, Ohkubo T, Hiyoshi M, Ono K, Senoo-Matsuda N, Shinohara O,
633 Yosshii F, Murakami M, Hartman PS, Tsuda M (2001) Enhancement of oxidative damage to cultured cells
634 and *Caenorhabditis elegans* by mitochondrial electron transport inhibitors. *IUBMB Life* 51: 263-8
635 Jeon SM (2016) Regulation and function of AMPK in physiology and diseases. *Exp Mol Med* 48: e245
636 Jia B, Crowder CM (2008) Volatile anesthetic preconditioning present in the invertebrate *Caenorhabditis*
637 *elegans*. *Anesthesiology* 108: 426-33
638 John GB, Shang Y, Li L, Renken C, Mannella CA, Selker JM, Rangell L, Bennett MJ, Zha J (2005) The
639 mitochondrial inner membrane protein mitofilin controls cristae morphology. *Mol Biol Cell* 16: 1543-54
640 Kandori H (2015) Ion-pumping microbial rhodopsins. *Front Mol Biosci* 2: 52
641 Lee H, Cho JS, Lambacher N, Lee J, Lee SJ, Lee TH, Gartner A, Koo HS (2008) The *Caenorhabditis elegans*
642 AMP-activated protein kinase AAK-2 is phosphorylated by LKB1 and is required for resistance to
643 oxidative stress and for normal motility and foraging behavior. *J Biol Chem* 283: 14988-93
644 Lee HP, Casadesus G, Zhu X, Lee HG, Perry G, Smith MA, Gustaw-Rothenberg K, Lerner A (2009) All-trans
645 retinoic acid as a novel therapeutic strategy for Alzheimer's disease. *Expert Rev Neurother* 9: 1615-21
646 Mello CC, Kramer JM, Stinchcomb D, Ambros V (1991) Efficient gene transfer in *C.elegans*:
647 extrachromosomal maintenance and integration of transforming sequences. *EMBO J* 10: 3959-70
648 Michiels C (2004) Physiological and pathological responses to hypoxia. *Am J Pathol* 164: 1875-82
649 Mihaylova MM, Shaw RJ (2011) The AMPK signalling pathway coordinates cell growth, autophagy and
650 metabolism. *Nat Cell Biol* 13: 1016-23
651 Murphy MP, Hartley RC (2018) Mitochondria as a therapeutic target for common pathologies. *Nat Rev*
652 *Drug Discov*
653 Okazaki A, Takagi S (2013) An optogenetic application of proton pump ArchT to *C. elegans* cells. *Neurosci*
654 *Res* 75: 29-34
655 Ozcan C, Palmeri M, Horvath TL, Russell KS, Russell RR, 3rd (2013) Role of uncoupling protein 3 in
656 ischemia-reperfusion injury, arrhythmias, and preconditioning. *Am J Physiol Heart Circ Physiol* 304:
657 H1192-200
658 Palace VP, Khaper N, Qin Q, Singal PK (1999) Antioxidant potentials of vitamin A and carotenoids and
659 their relevance to heart disease. *Free Radic Biol Med* 26: 746-61
660 Pena S, Sherman T, Brookes PS, Nehrke K (2016) The Mitochondrial Unfolded Protein Response Protects
661 against Anoxia in *Caenorhabditis elegans*. *PLoS One* 11: e0159989
662 Perry SW, Norman JP, Barbieri J, Brown EB, Gelbard HA (2011) Mitochondrial membrane potential
663 probes and the proton gradient: a practical usage guide. *Biotechniques* 50: 98-115
664 Porcelli AM, Ghelli A, Zanna C, Pinton P, Rizzuto R, Rugolo M (2005) pH difference across the outer
665 mitochondrial membrane measured with a green fluorescent protein mutant. *Biochem Biophys Res*
666 *Commun* 326: 799-804
667 Rizzuto R, De Stefani D, Raffaello A, Mammucari C (2012) Mitochondria as sensors and regulators of
668 calcium signalling. *Nat Rev Mol Cell Biol* 13: 566-78
669 Rost BR, Schneider F, Grauel MK, Wozny C, Bentz C, Blessing A, Rosenmund T, Jentsch TJ, Schmitz D,
670 Hegemann P, Rosenmund C (2015) Optogenetic acidification of synaptic vesicles and lysosomes. *Nat*
671 *Neurosci* 18: 1845-1852
672 Sanderson TH, Reynolds CA, Kumar R, Przyklenk K, Huttemann M (2013) Molecular mechanisms of
673 ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive
674 oxygen species generation. *Mol Neurobiol* 47: 9-23
675 Santo-Domingo J, Giacomello M, Poburko D, Scorrano L, Demarex N (2013) OPA1 promotes pH flashes
676 that spread between contiguous mitochondria without matrix protein exchange. *EMBO J* 32: 1927-40
677 Sawin ER, Ranganathan R, Horvitz HR (2000) *C. elegans* locomotory rate is modulated by the
678 environment through a dopaminergic pathway and by experience through a serotonergic pathway.
679 *Neuron* 26: 619-31

680 Schmeisser S, Priebe S, Groth M, Monajembashi S, Hemmerich P, Guthke R, Platzer M, Ristow M (2013)
681 Neuronal ROS signaling rather than AMPK/sirtuin-mediated energy sensing links dietary restriction to
682 lifespan extension. *Mol Metab* 2: 92-102
683 Shabalina IG, Nedergaard J (2011) Mitochondrial ('mild') uncoupling and ROS production: physiologically
684 relevant or not? *Biochem Soc Trans* 39: 1305-9
685 Shadel GS, Horvath TL (2015) Mitochondrial ROS signaling in organismal homeostasis. *Cell* 163: 560-9
686 Siddikuzzaman, Grace VM (2013) Antioxidant potential of all-trans retinoic acid (ATRA) and enhanced
687 activity of liposome encapsulated ATRA against inflammation and tumor-directed angiogenesis.
688 *Immunopharmacol Immunotoxicol* 35: 164-73
689 Solaini G, Baracca A, Lenaz G, Sgarbi G (2010) Hypoxia and mitochondrial oxidative metabolism. *Biochim*
690 *Biophys Acta* 1797: 1171-7
691 Sumii M, Furutani Y, Waschuk SA, Brown LS, Kandori H (2005) Strongly hydrogen-bonded water
692 molecule present near the retinal chromophore of Leptosphaeria rhodopsin, the bacteriorhodopsin-like
693 proton pump from a eukaryote. *Biochemistry* 44: 15159-66
694 Takahashi M, Takagi S (2017) Optical silencing of body wall muscles induces pumping inhibition in
695 *Caenorhabditis elegans*. *PLoS Genet* 13: e1007134
696 Tkatch T, Greotti E, Baranauskas G, Pendin D, Roy S, Nita LI, Wettmarshausen J, Prigge M, Yizhar O,
697 Shirihai OS, Fishman D, Hershfinkel M, Fleidervish IA, Perocchi F, Pozzan T, Sekler I (2017) Optogenetic
698 control of mitochondrial metabolism and Ca(2+) signaling by mitochondria-targeted opsins. *Proc Natl*
699 *Acad Sci U S A* 114: E5167-E5176
700 Trewin AJ, Bahr LL, Almast A, Berry BJ, Wei AY, Foster TH, Wojtovich AP (2019) Mitochondrial Reactive
701 Oxygen Species Generated at the Complex-II Matrix or Intermembrane Space Microdomain Have
702 Distinct Effects on Redox Signaling and Stress Sensitivity in *Caenorhabditis elegans*. *Antioxid Redox*
703 *Signal* 31: 594-607
704 Trewin AJ, Berry BJ, Wei AY, Bahr LL, Foster TH, Wojtovich AP (2018a) Light-induced oxidant production
705 by fluorescent proteins. *Free Radic Biol Med* 128: 157-164
706 Trewin AJ, Berry BJ, Wojtovich AP (2018b) Exercise and Mitochondrial Dynamics: Keeping in Shape with
707 ROS and AMPK. *Antioxidants (Basel)* 7
708 Tsalik EL, Hobert O (2003) Functional mapping of neurons that control locomotory behavior in
709 *Caenorhabditis elegans*. *J Neurobiol* 56: 178-97
710 Tsang WY, Lemire BD (2003) The role of mitochondria in the life of the nematode, *Caenorhabditis*
711 *elegans*. *Biochim Biophys Acta* 1638: 91-105
712 Viola HM, Hool LC (2017) Auto-regulation in the powerhouse. *Elife* 6
713 Wang X, Zhang X, Wu D, Huang Z, Hou T, Jian C, Yu P, Lu F, Zhang R, Sun T, Li J, Qi W, Wang Y, Gao F,
714 Cheng H (2017) Mitochondrial flashes regulate ATP homeostasis in the heart. *Elife* 6
715 Wang YT, Lim Y, McCall MN, Huang KT, Haynes CM, Nehrke K, Brookes PS (2019) Cardioprotection by the
716 mitochondrial unfolded protein response (UPR(mt)) requires ATF5. *Am J Physiol Heart Circ Physiol*
717 Waschuk SA, Bezerra AG, Jr., Shi L, Brown LS (2005) Leptosphaeria rhodopsin: bacteriorhodopsin-like
718 proton pump from a eukaryote. *Proc Natl Acad Sci U S A* 102: 6879-83
719 Wojtovich AP, DiStefano P, Sherman T, Brookes PS, Nehrke K (2012a) Mitochondrial ATP-sensitive
720 potassium channel activity and hypoxic preconditioning are independent of an inwardly rectifying
721 potassium channel subunit in *Caenorhabditis elegans*. *FEBS Lett* 586: 428-34
722 Wojtovich AP, Nadtochiy SM, Brookes PS, Nehrke K (2012b) Ischemic preconditioning: the role of
723 mitochondria and aging. *Exp Gerontol* 47: 1-7
724 Wojtovich AP, Nadtochiy SM, Urciuoli WR, Smith CO, Grunnet M, Nehrke K, Brookes PS (2013) A non-
725 cardiomyocyte autonomous mechanism of cardioprotection involving the SLO1 BK channel. *PeerJ* 1: e48
726 Xu M, Wang Y, Ayub A, Ashraf M (2001) Mitochondrial K(ATP) channel activation reduces anoxic injury
727 by restoring mitochondrial membrane potential. *Am J Physiol Heart Circ Physiol* 281: H1295-303

728 Yang JL, Mukda S, Chen SD (2018) Diverse roles of mitochondria in ischemic stroke. *Redox Biol* 16: 263-
729 275
730 Zhang L, Trushin S, Christensen TA, Bachmeier BV, Gateno B, Schroeder A, Yao J, Itoh K, Sesaki H, Poon
731 WW, Gyls KH, Patterson ER, Parisi JE, Diaz Brinton R, Salisbury JL, Trushina E (2016) Altered brain
732 energetics induces mitochondrial fission arrest in Alzheimer's Disease. *Sci Rep* 6: 18725
733
734

735 **Expanded view figures**



736
737


738 **Figure EV1 - mtON is targeted to mitochondria.**

739 **A** mtON tagged with GFP expressed in body wall muscle overlaps with MitoTracker™ Red
740 CMXRos stained mitochondria.

741 **B** Profile plot of a selected region demonstrating the overlapping signal intensity of GFP and
742 MitoTracker™ Red CMXRos determined using ImageJ software.

743

744



745

746 **Figure EV2 - Schematic of experimental conditions.**

747 **A** Expression control: baseline condition where animals express mtON, but have not been
748 supplemented with ATR or exposed to light. This condition is represented by the color black
749 throughout.


750 **B** Light control: condition exposed to light where mtON is illuminated but not supplemented with
751 ATR, resulting in an inactive proton pump. This condition is represented by the color gray
752 throughout.

753 **C** ATR control: condition supplemented with ATR but not exposed to light, where proton
754 pumping is possible but no light activation has occurred. This condition is represented by dark
755 green throughout.

756 **D** Active optogenetic condition: supplemented with ATR and exposed to light, where proton
757 pumping activity is expected. This condition is represented by bright green throughout.

758

759



760


761 **Figure EV3 - mtON increases the PMF and ATP synthesis light dose-dependently**

762 **A** Quantification of change in TMRE fluorescence with increasing light dose (increasing fluence
763 from left to right: 0, 0.016, 0.08, 0.096, 0.16, 0.24 J/cm²). Two-way ANOVA with Sidak's multiple
764 comparisons test, +ATR: 0 vs. 0.096 J/cm² *p = 0.0232, 0 vs. 0.24 J/cm² *p = 0.0149, 0.016 vs.
765 0.096 J/cm² *p = 0.0162, 0.016 vs. 0.16 J/cm² *p = 0.0376, 0.016 vs. 0.24 J/cm² *p = 0.0101. n
766 = 3 - 6 mitochondrial isolations.

767

768 **B** ATP levels in response to increasing illumination normalized to maximum ATP synthesis
769 given by succinate respiration (dotted line). 10 minute illumination time from Fig. 2E. Two-way
770 ANOVA with Sidak's multiple comparison test, -ATR: succinate vs. 1, 5 and 10 minutes light *p
771 < 0.0001. +ATR: succinate vs. 1 minute light, *p < 0.0001, 1 minute light vs. 5 minutes light *p =
772 0.0098, 1 minute light vs. 10 minutes light *p = 0.0001. n = 3 - 7 light treatments across 2
773 mitochondrial isolations.

774



775

776 Figure EV4 - mtON effects on respiration

777

778 **A** Respiratory control ratios (indicative of ability of isolated mitochondria to respond to energy
779 demand) were calculated by dividing the rate of O₂ consumption with ADP and succinate by the
780 rate after ADP was depleted. One-way ANOVA with Tukey's post hoc test, $p = 0.72$, $n = 6$
781 mitochondrial preparations. Bars are means \pm SEM.


782

783 **B** O₂ consumption rates under different states of respiration comparing the control conditions.
784 One-way ANOVA with Tukey's post hoc tests performed for each respiration state. ADP rate $p =$
785 0.66, Succinate rate $p = 0.61$. ADP exhausted rate $p = 0.83$. Bars are means \pm SEM. **C**
786 Representative traces depicting O₂ consumption rate. +/- light for mitochondria with ATR
787 present. Light exposure was 10 minutes before the addition of succinate. Traces show an initial
788 rapid depletion of ADP before transitioning to a lower rate of O₂ consumption.

789

790

791 **C** Activation of mtON decreases the amount of O₂ required to consume 50 nmoles ADP light
792 dose-dependently. Isolated mitochondria were exposed to light for the indicated time and then
793 succinate was added (example traces in panel c). Dark and 10 minute illumination data was
794 used for analysis in Fig. 2F. Linear regression showed a negative relationship between O₂
795 required to consume ADP and illumination time in mitochondria from animals with mtON that
796 were supplemented with ATR, $R^2 = 0.98$ $p = 0.007$, $n = 6$ mitochondrial preparations. Linear
797 regression shows no relationship between O₂ required to consume ADP and illumination in
798 mitochondria from animals with mtON not supplemented with ATR, $R^2 = 0.756$ $p = 0.130$, dark $n = 5$,
799 1 min light $n = 5$, 5 min light $n = 6$, 10 min light $n = 6$. Data are means \pm SEM.



800

801

Figure EV5 – ATR and light have no effect in wild type survival

802

803

804

805

A Same experimental conditions from Fig. 3A, here testing wild type animals. No difference in survival within ATR conditions, suggesting the interaction between ATR and light has no effect on its own. One-way ANOVA with Tukey's multiple comparison test. Again, ATR alone was protective (-ATR, -light vs. +ATR, -light $p = 0.0111$.)

806

807

808

B Same experimental conditions from Fig. 3B, here testing wild type animals, showing no difference in survival. One-way ANOVA with Tukey's multiple comparison test.

Table 1. *C. elegans* strains. Some strains were provided by the *C. elegans* Genetics Center (CGC).

Strain	Genotype	Abbreviation	Source	Notes
N2(Bristol)		wildtype	CGC	Wild type
APW32	<i>pha-1(e2123ts) III; jbmEx11 [pBJB20(P_{eff-3}::Mitofilin(N' 187 aa)::Mac::GFP), pC1 (pha-1(+))]</i>	mtON	this study	Ubiquitously expressed mitochondria-targeted light-activated proton pump
APW16	<i>pha-1(e2123ts) III; him-5 (e1490)V, jbmEx1 [pBJB16(P_{myo-3}::Mitofilin(187N'aa)::Mac::GFP), pC1 (pha-1(+))]</i>		this study	Mitochondria-targeted light-activated proton pump expressed only in body wall muscle cells strain
RB754	<i>aak-2(ok524) X.</i>	<i>aak-2</i>	CGC	AAK-2 loss of function mutant from the <i>C. elegans</i> Gene Knockout Project at the Oklahoma Medical Research Foundation, which was part of the International <i>C. elegans</i> Gene Knockout Consortium.